There is an increasing need to stratify patients based on drug response, drug efficiency and risk of side effects. As a result, the need to develop RNA-based biomarkers and measure RNA expression has increased considerably. RNAscope™ ISH technology enables molecular detection in a morphological context; providing the cellular resolution required to evaluate tissue heterogeneity and to potentially better screen and select patients.
ACD’s Feasibility and Prototype Biomarker Assay Development Program
ACD’s Professional Assay Services offer a Feasibility and Prototype Biomarker Assay Development Program to assist laboratories in streamlining their assay development process; providing detailed optimized protocols and complete probe verification, reproducibility testing and data analysis as required, on a number of platforms, sample-types, study criteria, as required.
Successful CDx Programs
Key Companion Diagnostic programs, recently reported via press release include:
Advanced Cell Diagnostics' RNAscope Technology Supports Biomarker-Selected Phase 2 Clinical Trial of Merrimack Pharmaceuticals' MM-121
HAYWARD, CALIFORNIA, March 9, 2015: Advanced Cell Diagnostics, Inc. announced that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121. Merrimack will utilize RNAscope to identify patients with Heregulin positive, locally advanced or metastatic non-small cell lung cancer, making this Merrimack's first MM-121 trial to include only patients with a high Heregulin biomarker profile. The RNAscope-based companion diagnostic test under development for Merrimack's MM-121 detects mRNA of heregulin, a ligand for the drug target of MM-121, ERBB3.
Bayer Develops Companion Diagnostic Test for Cancer Patients Together with Leica Biosystems
Leverkusen, December 21, 2016 – Bayer has entered into an agreement with Leica Biosystems to collaborate on the development of companion diagnostic tests based on tissue samples using RNAscope ® (a multiplex nucleic acid hybridization technology) and immunohistochemistry for cancer patients. Companion diagnostic tests aim to unlock molecular information from each patient to guide treatment decisions with targeted medications for cancer and other diseases.
Partnership with Leica Biosystems
Take a look at our short video, describing our partnership and continued progress to advance clinical diagnostics via innovative technologies including RNA ISH.
